ADH-6 TFA is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 TFA targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity,
Appearance:Solid
In Vitro:ADH-6 (25 μM, 10 h) TFA inhibits aggregation of pR248W (indicated by dot blot assay). ADH-6 (5 μM, 6 h) TFA dissociates intracellular mutant p53 aggregates in MIA PaCa-2 cells. ADH-6 (0-10 μM, 24 or 48 h) TFA causes selective cytotoxicity in can
In Vivo:ADH-6 (intraperitoneal injection, 15mg/kg, every 2 days, for a total of 12 doses) TFA causes regression of mutant p53-bearing tumors. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MIA P
Biological Activity:ADH-6 TFA is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 TFA targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity,
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.